Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.
The National Medical Commission (NMC) has issued Guidelines for the competency-based postgraduate training programme for MCh ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback